Ariad Pharmaceuticals Inc fka ARIA

[oldchemist4]

Agreed the 2 year follow-up will receive the most attention, as it should.

But a positive presentation on 1st-line would be well received too, especially as it would get around all the issues about AEs being due to previous medication(s). Yes - a new trial, of course, but some good data here would be enough for people to think about a 1st-line development program. And that would do the pps well.

But hey, let's hope all 10 posters go well, the presenters look good and field all the questions, the audience pays attention, and that there are lots of people in the audience with money looking to invest in the next big drug.

I sure feel for those who are presenting - good luck to any of you who might read this.